2023 | Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results | Gutierrez, Martin; Lam, Wei-Sen; Hellmann, Matthew D; Gubens, Matthew A; Aggarwal, Charu; Tan, Daniel Shao Weng; Felip, Enriqueta; Chiu, Joanne W Y; Lee, Jong-Seok; CHIH-HSIN YANG ; Garon, Edward B; Finocchiaro, Giovanna; Ahn, Myung-Ju; Luft, Alexander; Landers, Gregory A; Basso, Andrea; Ma, Hua; Kobie, Julie; Palcza, John; Cristescu, Razvan; Fong, Lawrence; Snyder, Alexandra; Yuan, Jianda; Herbst, Roy S | Nature medicine | 3 | 0 | |
2023 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study | Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann; CHIH-HUNG HSU | The Lancet. Oncology | 22 | | |